BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca (AZN) Release: New Study Shows Patients Experience Asthma Variability, Despite Strict Adherence To Treatment Guidelines


10/19/2005 5:12:13 PM

BOSTON, Nov. 15 /PRNewswire-FirstCall/ -- A study presented today at the 62nd Annual Meeting of the American College of Allergy, Asthma and Immunology shows that many patients with asthma continue to experience variability of disease control, despite strict adherence to treatment guidelines published by the National Heart, Lung and Blood Institute.(1) Variability in asthma control leads to continued disease symptoms and increased resource utilization, even when the disease is closely managed.

Although patients enrolled in the study experienced reductions in hospitalizations, emergency visits and clinic visits, researchers found important differences between those classified as having "high variability" and those with "low variability" of disease symptoms. Specifically:

   -- Patients in the high variability group experienced greater overall
      direct and indirect costs, measured by number of emergency department
      visits, hospitalizations and days lost from work, school or daily
      activities of living.  These patients also experienced more "sick
      visits," measured by unscheduled routine follow-up visits to primary
      care physicians, asthma clinics or urgent care facilities than those
      in the low variability group.(1)
   -- Hospitalization, emergency room visits and clinic visit costs for
      treating asthma of high variability patients were estimated at $163
      per patient per month, twice the cost for treating low variability
      patients ($81 per patient per month).
   -- 74 percent of patients in the high variability group used rescue
      bronchodilators daily for more than half of the weeks of the
      observation period, compared to less than half (47 percent) of the
      patients in the low variability group.(1)
   -- Asthma interrupted daily activity more often for patients in the high
      variability group.  On average, high variability patients reported
      that asthma caused them to miss work, school, exercise or social
      activities 1.84 days per patient per month.  Low variability patients
      reported missing activities 1.25 days per patient per month.(1)

"Asthma is a highly variable disease, and patients may continue to suffer from symptoms as a result, despite adherence to practice guidelines," said Ileen Gilbert, MD, Professor of Medicine, Medical College of Wisconsin, lead investigator of the study. "We still need to know more about the underlying pathophysiology of the disease as well as more about environmental factors that trigger events and how to modify them in order to fully treat and reduce costs of this complicated disorder."

Study Design and Methodology

The analysis of the study, supported by AstraZeneca, assessed asthma variability in 125 inner-city patients (72 percent female; 68 percent minority [African- and Hispanic-American]; 80 percent treated by primary care physicians) in a period beginning six months prior to enrollment into an NHLBI guidelines-directed clinical and education intervention to minimize barriers to adherence, and ending six months following enrollment. Patients were stratified into two groups: those with high variability in asthma, and those with low variability. For purposes of the study, variability was defined as the number of fluctuations in NAEPP symptom class in the six-month post- intervention period. The 62 patients in the high variability group changed their NAEPP symptom class about once every other month, or more frequently. All other patients were classified as having symptoms in the low variability group.

About Asthma

Asthma is one of the most serious chronic medical conditions in the United States. In 2002, it was estimated that 20 million Americans have asthma. Of these, nearly 12 million Americans had an asthma attack or episode in the past year. Additionally, it is estimated that more than 30 million Americans, or about 10 percent of the U.S. population, have been diagnosed with asthma at some point in their lives.(2)

Asthma is a reversible obstructive lung disease, caused by increased reaction of the airways to various stimuli, such as cigarette smoke, airborne molds, pollens, dust, animal dander, exercise, cold air, many household and industrial products, air pollutants, scents or simple stress. It is a chronic inflammatory condition that usually leads to breathing problems known as "episodes" - a series of events that result in narrowed airways - which is responsible for the difficulty in breathing with the familiar wheeze.(3) Although each person reacts differently to the factors that may trigger asthma, it can be a life-threatening disease if it is not properly managed. According to the American Lung Association, more than 4,200 Americans died from asthma in 2001.(2)

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is an $8.7 billion healthcare business with more than 11,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com/.

(1) Gilbert IA, Perry SM, Olivares A, et al. Resource utilization associated with asthma variability in patients with mild, moderate, or severe persistent asthma adhering to national asthma education prevention program therapy guidelines. Abstract presented at 62nd Annual Meeting of the American College of Allergy, Asthma and Immunology, November 12, 2004 (2) Trends in Asthma Morbidity and Mortality, American Lung Association, April 2004 (3) Asthma in Adults Fact Sheet, American Lung Association, July 2003

AstraZeneca

CONTACT: Cindy Callaghan of AstraZeneca, +1-302-886-2959,cynthia.callaghan@astrazeneca.com



Read at BioSpace.com

   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES